NasdaqGS:ALMSPharmaceuticals
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors?
Alumis Inc. has reported first-quarter 2026 results alongside past Phase 3 data showing strong efficacy for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis, while revenue declined to US$1.74 million and net loss reached US$93.05 million.
A key insight is that Alumis is pairing these psoriasis results with plans for a New Drug Application in late 2026 and potentially pivotal systemic lupus erythematosus data in the third quarter of 2026, positioning...